Discontinued — last reported Q4 '24

Other

Stock-Based Comp

Insmed Stock-Based Comp remained flat by 0.0% to 1.2% in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 235.7%, from 0.4% to 1.2%. Over 2 years (FY 2023 to FY 2025), Stock-Based Comp shows an upward trend with a 295.8% CAGR. This is a positive signal — lower values indicate better performance for this metric.

Analysis

StatementIncome Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2014
Last reportedQ4 2024

How to read this metric

An increase indicates that a larger portion of equity compensation is creating a tax drag, potentially impacting net income.

Detailed definition

This metric quantifies the impact of non-deductible share-based compensation on the effective tax rate. It serves as a b...

Peer comparison

Standard tax reconciliation line item for companies with heavy reliance on stock-based incentives.

Metric ID: other_effective_income_tax_rate_reconciliation_nondeduct_dd189b

Historical Data

3 years
 FY'23FY'24FY'25
Value-0.3%1.4%4.7%
YoY Change—+566.7%+235.7%
Range-0.3% – 4.7%
CAGR+295.8%
Avg YoY Growth+401.2%
Median YoY Growth+401.2%
Current Streak2+ years growth

Frequently Asked Questions

What is Insmed's stock-based comp?
Insmed (INSM) reported stock-based comp of 1.2% in Q4 2025.
How has Insmed's stock-based comp changed year-over-year?
Insmed's stock-based comp increased by 235.7% year-over-year, from 0.4% to 1.2%.
What is the long-term trend for Insmed's stock-based comp?
Over 2 years (2023 to 2025), Insmed's stock-based comp has grown at a 295.8% compound annual growth rate (CAGR), from -0.3% to 4.7%.
What does stock-based comp mean?
The percentage point impact of non-deductible stock compensation on the effective tax rate.